2.800EUR+3.32%Mkt Cap: 130.53M EURP/E: —Last update: 2026-05-14
Heidelberg Pharma AG, a biopharmaceutical company, focuses on oncology and antibody targeted amanitin conjugates (ATAC) in Germany, Europe, China, the United States, and internationally. The company's lead product candid…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Valuation
P/E (Trailing)—
P/E (Forward)-13.87
PEG5.46
P/B-11.97
P/S49.22
EV/EBITDA-2.65
EV/Revenue46.51
EPS (TTM)-0.87
EPS (Forward)-0.20
Cash Flow & Leverage
FCF Yield-14.11%
FCF Margin-694.49%
Operating CF-31.60M EUR
CapEx (TTM)135.05K EUR
Net Debt/EBITDA0.20
Net Debt-9.18M EUR
Technical
SMA 502.879 (-2.7%)
SMA 2003.076 (-9.0%)
Beta—
S&P 52W Chg24.23%
Avg Vol (30d)2.93K
Avg Vol (10d)1.30K
Technical Indicators
RSI (14)48.9
MACD-0.0251
MACD Signal-0.0266
MACD Hist.+0.0015
BB Upper2.870 EUR
BB Middle2.788 EUR
BB Lower2.705 EUR
BB Width5.91%
ATR (14)0.0991 EUR
Vol Ratio (20d)0.13x
52W Range
2.33016% of range5.360
52W High5.360 EUR
52W Low2.330 EUR
Profitability
Gross Margin81.31%
EBITDA Margin0.00%
Profit Margin-2901.15%
Oper. Margin-107.24%
ROE387.26%
ROA-110.87%
Revenue Growth220.20%
Earnings Growth—
Balance Sheet
Debt/Equity-0.01
Current Ratio2.40
Quick Ratio1.29
Book Value/Sh-0.2330 EUR
Cash/Share0.1950 EUR
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 EUR
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:4
Split DateJul 18, 2014
Ownership
Shares Out.46.78M
Float10.12M
Insiders79.00%
Institutions2.02%
Analyst Consensus
Rating—
Target (Mean)6.750 EUR
Target Range5.500 EUR – 8.000 EUR
# Analysts2
Company
Market Cap130.53M EUR
Enterprise Value123.35M EUR
Revenue (TTM)2.65M EUR
Gross Profit1.19M EUR
Net Income (TTM)-42.28M EUR
Revenue/Share0.0560 EUR
Fiscal Year EndDec 2019
MR QuarterFeb 2026
Employees70
Last Price2.800 EUR
CountryDE
SectorHealthcare
IndustryBiotechnology
ISINDE000A11QVV0